Literature DB >> 23200914

High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.

Leslie Cope1, Ren-Chin Wu, Ie-Ming Shih, Tian-Li Wang.   

Abstract

OBJECTIVES: Structural aberration in chromosomes characterizes almost all human solid cancers and analysis of those alterations may reveal the history of chromosomal instability. However, the clinical significance of massive chromosomal abnormality in ovarian high-grade serous carcinoma (HGSC) remains elusive. In this study, we addressed this issue by analyzing the genomic profiles in 455 ovarian HGSCs available from The Cancer Genome Atlas (TCGA).
METHODS: DNA copy number, mRNA expression, and clinical information were downloaded from the TCGA data portal. A chromosomal disruption index (CDI) was developed to summarize the extent of copy number aberrations across the entire genome. A Cox regression model was applied to identify factors associated with poor prognosis. Genes whose expression was associated with CDI were identified by a 2-stage multivariate linear regression and were used to find enriched pathways by Ingenuity Pathway Analysis.
RESULTS: Multivariate survival analysis showed that a higher CDI was significantly associated with a worse overall survival in patients. Interestingly, the pattern of DNA copy number alterations across all the chromosomes was similar between tumors with high and low CDI, suggesting they did not arise from different mechanisms. We also observed that expression of several genes was highly correlated with the CDI, even after adjusting for local copy number variation. We found that molecular pathways involving DNA damage response and mitosis were significantly enriched in these CDI-correlated genes.
CONCLUSION: Our results provide a new insight into the role of chromosomal rearrangement in the development of HGSC and the promise of applying CDI in risk-stratifying HGSC patients, perhaps for different clinical managements. The genes whose expression is correlated with CDI are worthy of further study to elucidate the mechanism of chromosomal instability in HGSC.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23200914      PMCID: PMC4364416          DOI: 10.1016/j.ygyno.2012.11.031

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  36 in total

1.  A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.

Authors:  Bong-Gun Ju; Victoria V Lunyak; Valentina Perissi; Ivan Garcia-Bassets; David W Rose; Christopher K Glass; Michael G Rosenfeld
Journal:  Science       Date:  2006-06-23       Impact factor: 47.728

2.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

Review 3.  Recurrent chromosome aberrations in cancer.

Authors:  F Mitelman
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

Review 4.  Polo-like kinases and oncogenesis.

Authors:  Frank Eckerdt; Juping Yuan; Klaus Strebhardt
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

Review 5.  Polo-like kinases (Plks) and cancer.

Authors:  Noriyuki Takai; Ryoji Hamanaka; Jun Yoshimatsu; Isao Miyakawa
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

6.  Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Authors:  Kuan-Ting Kuo; Bin Guan; Yuanjian Feng; Tsui-Lien Mao; Xu Chen; Natini Jinawath; Yue Wang; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

Review 7.  Chromosome aberrations in solid tumors.

Authors:  Donna G Albertson; Colin Collins; Frank McCormick; Joe W Gray
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

Review 8.  Chromosome fragile sites.

Authors:  Sandra G Durkin; Thomas W Glover
Journal:  Annu Rev Genet       Date:  2007       Impact factor: 16.830

Review 9.  Hallmarks of 'BRCAness' in sporadic cancers.

Authors:  Nicholas Turner; Andrew Tutt; Alan Ashworth
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

10.  DNA instability at chromosomal fragile sites in cancer.

Authors:  Laura W Dillon; Allison A Burrow; Yuh-Hwa Wang
Journal:  Curr Genomics       Date:  2010-08       Impact factor: 2.236

View more
  13 in total

1.  Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors.

Authors:  Wenya Linda Bi; Noah F Greenwald; Shakti H Ramkissoon; Malak Abedalthagafi; Shannon M Coy; Keith L Ligon; Yu Mei; Laura MacConaill; Matt Ducar; Le Min; Sandro Santagata; Ursula B Kaiser; Rameen Beroukhim; Edward R Laws; Ian F Dunn
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

2.  Mutations in exon 11 (11.1 and 11.2) of the BRCA1 gene and risk factors for breast cancer in Burkina Faso.

Authors:  Isabelle Touwendpoulimdé Kiendrebeogo; Abdou Azaque Zoure; Fabienne Ingrid Zongo; Abdoul Karim Ouattara; Marie N L Ouedraogo; Jospin Amegnona; Albert Théophane Yonli; Bagora Bayala; Nayi Zongo; Aboubacar Hierrhum Bambara; Alexis Yobi Sawadogo; Theodora M Zohoncon; Dorcas Obiri-Yeboah; Jacques Simpore
Journal:  J Public Health Afr       Date:  2022-05-25

Review 3.  The rise of genomic profiling in ovarian cancer.

Authors:  Rebecca A Previs; Anil K Sood; Gordon B Mills; Shannon N Westin
Journal:  Expert Rev Mol Diagn       Date:  2016-12       Impact factor: 5.225

4.  Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup.

Authors:  Jen-Chieh Lee; Tzu-Pin Lu; Chun A Changou; Cher-Wei Liang; Hsien-Neng Huang; Alexandra Lauria; Hsuan-Ying Huang; Chin-Yao Lin; Ying-Cheng Chiang; Ben Davidson; Ming-Chieh Lin; Kuan-Ting Kuo
Journal:  Mod Pathol       Date:  2016-06-03       Impact factor: 7.842

5.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.

Authors:  Hui Zhang; Tao Liu; Zhen Zhang; Samuel H Payne; Bai Zhang; Jason E McDermott; Jian-Ying Zhou; Vladislav A Petyuk; Li Chen; Debjit Ray; Shisheng Sun; Feng Yang; Lijun Chen; Jing Wang; Punit Shah; Seong Won Cha; Paul Aiyetan; Sunghee Woo; Yuan Tian; Marina A Gritsenko; Therese R Clauss; Caitlin Choi; Matthew E Monroe; Stefani Thomas; Song Nie; Chaochao Wu; Ronald J Moore; Kun-Hsing Yu; David L Tabb; David Fenyö; Vineet Bafna; Yue Wang; Henry Rodriguez; Emily S Boja; Tara Hiltke; Robert C Rivers; Lori Sokoll; Heng Zhu; Ie-Ming Shih; Leslie Cope; Akhilesh Pandey; Bing Zhang; Michael P Snyder; Douglas A Levine; Richard D Smith; Daniel W Chan; Karin D Rodland
Journal:  Cell       Date:  2016-06-29       Impact factor: 41.582

6.  Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data.

Authors:  Andrew E Dellinger; Andrew B Nixon; Herbert Pang
Journal:  Cancer Inform       Date:  2014-07-28

7.  Somatic mutations favorable to patient survival are predominant in ovarian carcinomas.

Authors:  Wensheng Zhang; Andrea Edwards; Erik Flemington; Kun Zhang
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

Review 8.  Multi-layered cancer chromosomal instability phenotype.

Authors:  Anna V Roschke; Ester Rozenblum
Journal:  Front Oncol       Date:  2013-12-11       Impact factor: 6.244

9.  Genomic profiling identifies GPC5 amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas.

Authors:  M Herman Chui; Cherry Have; Lien N Hoang; Patricia Shaw; Cheng-Han Lee; Blaise A Clarke
Journal:  J Pathol Clin Res       Date:  2018-01-24

Review 10.  Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer.

Authors:  Sarah Blagden; Mai Abdel Mouti; James Chettle
Journal:  Wiley Interdiscip Rev RNA       Date:  2017-08-01       Impact factor: 9.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.